- Beat earnings estimates in all of the last 4 quarters
- Excellent financial health (Piotroski 7/9)
- High gross margin of 72.7%
Evaluation of GlaxoSmithKline stock downgraded after the last trading session
(Updated on Jul 13, 2026)
The GlaxoSmithKline stock price fell by -0.93% on the last day (Monday, 13th Jul 2026) from $52.78 to $52.29. During the last trading day the stock fluctuated 1.80% from a day low at $51.75 to a day high of $52.68. The price has fallen in 6 of the last 10 days and is down by -0.4% for this period. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -978 thousand shares and in total, 2 million shares were bought and sold for approximately $98.82 million.
The stock lies in the middle of a wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -5.08% during the next 3 months and, with a 90% probability hold a price between $45.25 and $53.32 at the end of this 3-month period.
GSK Signals & Forecast
The GlaxoSmithKline stock holds a sell signal from the short-term Moving Average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock. On further gains, the stock will meet resistance from the short-term Moving Average at approximately $52.88. On a fall, the stock will find some support from the long-term average at approximately $51.71. A break-up through the short-term average will send a buy signal, whereas a breakdown through the long-term average will send a sell signal. A buy signal was issued from a pivot bottom point on Tuesday, June 02, 2026, and so far it has risen 6.71%. Further rise is indicated until a new top pivot has been found. Some negative signals were issued as well, and these may have some influence on the near short-term development. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell together with the price during the last trading day and this reduces the overall risk as volume should follow the price movements.
Support, Risk & Stop-loss for GlaxoSmithKline stock
GlaxoSmithKline finds support from accumulated volume at $51.40 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
In general the stock tends to have very controlled movements and with good liquidity the risk is considered very low in this stock. During the last day, the stock moved $0.93 between high and low, or 1.80%. For the last week the stock has had daily average volatility of 1.50%.
Our recommended stop-loss: $49.72 (-4.92%) (This stock has very low daily movements and this gives very low risk. There is a buy signal from a pivot bottom found 27 days ago.)
Trading Expectations (GSK) For The Upcoming Trading Day Of Tuesday 14th
For the upcoming trading day on Tuesday, 14th we expect GlaxoSmithKline PLC to open at $52.24, and during the day (based on 14 day Average True Range), to move between $51.74 and $52.84, which gives a possible trading interval of +/-$1.10 (+/-2.13%) up or down from last closing price. If GlaxoSmithKline PLC takes out the full calculated possible swing range there will be an estimated 2.13% move between the lowest and the highest trading price during the day.
Since the stock is closer to the resistance from accumulated volume at $52.31 (0.04%) than the support at $51.40 (1.70%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.
Is GlaxoSmithKline PLC stock A Buy?
GlaxoSmithKline holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Buy to a Hold candidate.
Current score:
0.428
Hold/Accumulate
Downgraded
Predicted Fair Opening Price
Predicted fair opening price on July 14, 2026 - $52.24 ( 0.0956%).
Want to trade but not sure how?
Our step-by-step guide can help.
Skip the guide? Open account with our trusted broker* 
*Your capital is at risk
GSK Performance
Trading levels for GSK
Fibonacci Support & Resistance Levels
| Level | Price | |
|---|---|---|
| R3 | 53.17 | 1.68% |
| R2 | 52.81 | 1.00% |
| R1 | 52.60 | 0.584% |
| Price | 52.29 | |
| S1 | 51.88 | -0.775% |
| S2 | 51.67 | -1.19% |
| S3 | 51.31 | -1.87% |
Accumulated Volume Support & Resistance Levels
| Level | Price | |
|---|---|---|
| R3 | 54.47 | 4.17% |
| R2 | 54.44 | 4.11% |
| R1 | 52.31 | 0.0382% |
| Price | 52.29 | |
| S1 | 51.40 | -1.70% |
| S2 | 51.25 | -1.99% |
| S3 | 50.90 | -2.66% |
GSK Dividend Payout History
| # | Ex-Date | Pay Date | Amount | Yield | |
|---|---|---|---|---|---|
| 1 | Apr 29, 2026 | May 15, 2026 | Jul 09, 2026 | $0.0100 | 0.0194% |
| 2 | Feb 20, 2026 | Feb 20, 2026 | Apr 09, 2026 | $0.486 | 0.82% |
| 3 | Nov 14, 2025 | Nov 14, 2025 | Jan 08, 2026 | $0.410 | 0.87% |
| 4 | Aug 15, 2025 | Aug 15, 2025 | Oct 09, 2025 | $0.421 | 1.13% |
| 5 | May 16, 2025 | May 16, 2025 | Jul 10, 2025 | $0.422 | 1.10% |
FAQ
Click here for our free guide on how to buy GlaxoSmithKline Stock.
Buy GSK